PANHPVAX / German Cancer Research Center, University of Heidelberg - LARVOL DELTA

A safe and potentiated multi-type HPV L2-E7 nanoparticle vaccine with combined prophylactic and therapeutic activity. (PubMed, NPJ Vaccines) - "cPANHPVAX safety was further improved by deletion of the pRb-binding domains of E7. Our dual-purpose vaccine holds great potential for clinical translation as an immune-treatment capable of targeting active infections as well as established HPV-related malignancies, thus benefiting both uninfected and infected individuals."

Journal • Cervical Cancer • Human Papillomavirus Infection • Infectious Disease • Oncology

Inter-epitope spacer variation within polytopic L2-based human papillomavirus antigens affects immunogenicity. (PubMed, NPJ Vaccines) - "Recently, we have developed two HPV vaccine antigens - PANHPVAX and CUT-PANHPVAX- both based on heptameric nanoparticle antigens displaying polytopes of the L2 major cross-neutralizing epitopes of eight mucosal and twelve cutaneous HPV types, respectively...Furthermore, mAb affinity toward individual spacer variants was well correlated with their neutralizing antibody induction capacity, indicating that the mAb affinity assay predicts L2-based antigen immunogenicity. These observations provide insights on the development and optimization of L2-based HPV vaccines."

Journal • Oncology

PANHPVAX, Study of a New HPV Vaccine in Healthy Volunteers (clinicaltrials.gov) - P1 | N=45 | Recruiting | Sponsor: German Cancer Research Center | Not yet recruiting ➔ Recruiting | Trial completion date: Aug 2023 ➔ Dec 2024 | Trial primary completion date: Aug 2023 ➔ Dec 2024

Enrollment open • Trial completion date • Trial primary completion date • Oncology

NEXT GENERATION L2-BASED HPV VACCINES CROSS-PROTECT AGAINST CUTANEOUS PAPILLOMAVIRUS INFECTION AND TUMOR DEVELOPMENT (IPVC 2023) - "We tested two novel L2-based HPV vaccine candidates, HPV16 RG1-VLP and CUT-PANHPVAX, in the preclinical model Mastomys coucha...Protected animals not even showed microscopical signs of MnPV infection in the skin.Conclusions For the first time, our study shows the proof-of-principle of two next generation L2-based vaccines that are currently entering clinical trials in an infection model with its genuine PV. Even across different PV genera, these L2-based vaccines have a promising efficacy to protect against HPV-induced skin tumors."

Infectious Disease • Oncology • Skin Cancer

Next generation L2-based HPV vaccines cross-protect against cutaneous papillomavirus infection and tumor development. (PubMed, Front Immunol) - "In this exploratory study, we tested two novel HPV vaccine candidates, HPV16 RG1-VLP and CUT-PANHPVAX, in the preclinical natural infection model Mastomys coucha...For the first time, our study shows the proof-of-principle of next generation L2-based vaccines even across different PV genera in an infection animal model with its genuine PV. It provides fundamental insights into the humoral immunity elicited by L2-based vaccines against PV-induced skin tumors, with important implications to the design of next generation HPV vaccines."

Journal • Genetic Disorders • Infectious Disease • Non-melanoma Skin Cancer • Skin Cancer • Solid Tumor